Asset
LUVELTAMAB TAZEVIBULIN
SUTRO BIOPHARMA INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05200364 | phase1 | terminated | 2022-03-22 | 2025-06-01 | Sutro Biopharma, Inc. | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer |
| NCT06679582 | phase1_2 | terminated | 2024-12-04 | 2025-06-01 | Sutro Biopharma, Inc. | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML |
| NCT05870748 | phase2_3 | terminated | 2023-07-12 | 2025-08-26 | Sutro Biopharma, Inc. | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 |
| NCT03748186 | phase1 | completed | 2019-02-01 | 2024-06-04 | Sutro Biopharma, Inc. | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers |
| NCT06555263 | phase2 | withdrawn | 2024-08-21 | 2025-05-01 | Sutro Biopharma, Inc. | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.